← All stories
Markets
AstraZeneca (LSE:AZN): Why Are Traders Rethinking the Oncology Story Today?
Highlights A licensing agreement tied to the company's oncology franchise landed alongside fresh trial readouts. New lung cancer data and a European approval in breast cancer widened the treatment footprint. A multi-tranche debt admission t…
Covered by 1 outlet
All coverage · 1 article